{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:17:37Z","timestamp":1793733457125,"version":"4.6.1"},"reference-count":242,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Prostate cancer (PC) is one of the most common cancers that is diagnosed in about 10-15% of men in old age. It seems that the current treatments are not effective, and this leads to prostate cancer becoming the second-deadliest cancer. Treatments such as chemotherapy, radiotherapy, androgen deprivation therapy (ADT), and surgery are among these treatments. However, the possibility of disease recurrence after these treatments is high. Therefore, other methods have become necessary, and PC treatment is changing. One of the methods that has received much attention today is immunotherapy. Immunotherapy includes all interventions that help to treat cancer or any other disease by affecting the immune system\u2019s responses. For this purpose, cytokines, cell therapy, and antibody-based methods can be used. Antibody-based treatments include immune checkpoint inhibitors (ICIs), and due to the high expression of immune checkpoint (ICP) molecules on the surface of prostate cancer cells and cancer stromal cells, these treatments have yielded promising results. Also, combining them with chemotherapy, surgery, and radiotherapy can help increase their efficiency. This review first updates standard treatments\u2019 therapeutic efficacy and risk factors. Then, we will talk about different types of immunotherapies, emphasizing ICIs.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1583363","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T06:12:05Z","timestamp":1750227125000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Prostate cancer immunotherapy-based strategies: an updated review emphasizing immune checkpoint inhibitors"],"prefix":"10.3389","volume":"16","author":[{"given":"Hua","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaojun","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-077738","article-title":"Prostate cancer incidence and mortality in Europe and implications for screening activities: population based study","volume":"386","author":"Vaccarella","year":"2024","journal-title":"bmj"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00705-1","article-title":"Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis","volume":"23","author":"Kishan","year":"2022","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-021-00470-4","article-title":"Treatment and trials in non-metastatic castration-resistant prostate cancer","volume":"18","author":"Lokeshwar","year":"2021","journal-title":"Nat Rev Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2022.10.003","article-title":"Prevalence and natural history of non-metastatic castrate resistant prostate cancer: a population-based analysis","volume":"21","author":"Hird","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41391-024-00803-5","article-title":"A multidisciplinary approach to address unmet needs in the management of patients with non-metastatic castration-resistant prostate cancer","author":"Shore","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"102525","DOI":"10.1016\/j.ctrv.2023.102525","article-title":"nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives","volume":"115","author":"Berruti","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071792","article-title":"Apalutamide, darolutamide and enzalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC)","volume":"14","author":"Cattrini","year":"2022","journal-title":"Cancers"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3835","article-title":"An FDA review of drug development in nonmetastatic castration-resistant prostate cancer","volume":"26","author":"Brave","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/10600280231155441","article-title":"Updates in the treatment of non-metastatic castrate-resistant prostate cancer: the benefit of second-generation androgen receptor antagonists","volume":"57","author":"Hadfield","year":"2023","journal-title":"Ann Pharmacother"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.11774.x","article-title":"Androgen deprivation therapy: evidence-based management of side effects","volume":"111","author":"Ahmadi","year":"2013","journal-title":"BJU Int"},{"key":"B11","article-title":"ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury","volume":"29","author":"Crawford","year":"2015","journal-title":"Oncology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v115:11","article-title":"Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer","volume":"115","author":"Taylor","year":"2009","journal-title":"Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1111\/j.1743-6109.2011.02590.x","article-title":"Androgen deprivation therapy in prostate cancer: focusing on sexual side effects","volume":"9","author":"Corona","year":"2012","journal-title":"J Sexual Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-020-0335-7","article-title":"Intermittent versus continuous androgen deprivation therapy for advanced prostate cancer","volume":"17","author":"Perera","year":"2020","journal-title":"Nat Rev Urol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2011.72","article-title":"Immunotherapy for the treatment of prostate cancer","volume":"8","author":"Di Lorenzo","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nature21676","article-title":"Effective combinatorial immunotherapy for castration-resistant prostate cancer","volume":"543","author":"Lu","year":"2017","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"New Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3390\/cancers14051245","article-title":"Immune checkpoint inhibitors in advanced prostate cancer: current data and future perspectives","volume":"14","author":"Rebuzzi","year":"2022","journal-title":"Cancers"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30327-3","article-title":"Evolving adoptive cellular therapies in urological Malignancies","volume":"18","author":"Wong","year":"2017","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"5346","DOI":"10.1038\/s41467-023-40852-3","article-title":"Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models","volume":"14","author":"Porter","year":"2023","journal-title":"Nat Commun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-021-00488-8","article-title":"The potential of CAR T cell therapy for prostate cancer","volume":"18","author":"Wolf","year":"2021","journal-title":"Nat Rev Urol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2015.12.022","article-title":"Regulation of prostate cancer progression by the tumor microenvironment","volume":"380","author":"Shiao","year":"2016","journal-title":"Cancer Lett"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1965","article-title":"Inherent and tumor-driven immune tolerance in the prostate microenvironment impairs natural killer cell antitumor activity","volume":"76","author":"Pasero","year":"2016","journal-title":"Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-020-07058-y","article-title":"Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy","volume":"20","author":"Bou-Dargham","year":"2020","journal-title":"BMC Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.drup.2019.07.004","article-title":"Immune checkpoint inhibitor combinations: Current efforts and important aspects for success","volume":"45","author":"Kon","year":"2019","journal-title":"Drug Resist Updates"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00351","article-title":"Exploiting synergy: immune-based combinations in the treatment of prostate cancer","volume":"4","author":"Burotto","year":"2014","journal-title":"Front Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrurol.2017.167","article-title":"The inflammatory microenvironment and microbiome in prostate cancer development","volume":"15","author":"Sfanos","year":"2018","journal-title":"Nat Rev Urol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/biot.200500044","article-title":"Cancer immunotherapy","volume":"1","author":"Schuster","year":"2006","journal-title":"Biotechnol J: Healthc Nutr Technol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nri2817","article-title":"Prostate cancer as a model for tumour immunotherapy","volume":"10","author":"Drake","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41568-019-0186-9","article-title":"Improving cancer immunotherapy through nanotechnology","volume":"19","author":"Goldberg","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3258","article-title":"Cancer immunotherapy via dendritic cells","volume":"12","author":"Palucka","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01462-y","article-title":"Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial","volume":"27","author":"Creelan","year":"2021","journal-title":"Nat Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41591-021-01301-0","article-title":"Vaccine development for emerging infectious diseases","volume":"27","author":"Excler","year":"2021","journal-title":"Nat Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.08.004","article-title":"Cancer immunotherapy by dendritic cells","volume":"29","author":"Melief","year":"2008","journal-title":"Immunity"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0531","article-title":"Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions","volume":"14","author":"Handy","year":"2017","journal-title":"Future Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1592\/phco.31.8.813","article-title":"Cancer immunotherapy: sipuleucel-T and beyond","volume":"31","author":"Hammerstrom","year":"2011","journal-title":"Pharmacother: J Hum Pharmacol Drug Ther"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-018-0333-y","article-title":"Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine","volume":"6","author":"Wargowski","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201744","article-title":"Human prostate tumor antigen\u2013specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade","volume":"189","author":"Olson","year":"2012","journal-title":"J Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"dju268","DOI":"10.1093\/jnci\/dju268","article-title":"Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer","volume":"106","author":"Fong","year":"2014","journal-title":"J Natl Cancer Institute"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002903","article-title":"IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"9","author":"Pachynski","year":"2021","journal-title":"J ImmunoTher Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.7282","article-title":"Active cellular immunotherapy in the desert of advanced prostate cancer","volume":"8","author":"Patel","year":"2022","journal-title":"JAMA Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"18192","DOI":"10.18632\/oncotarget.v6i20","article-title":"Phase I\/II clinical trial of dendritic-cell based immunotherapy (DCVAC\/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer","volume":"6","author":"Podrazil","year":"2015","journal-title":"Oncotarget"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.7298","article-title":"Efficacy and safety of autologous dendritic cell\u2013based immunotherapy, docetaxel, and prednisone vs placebo in patients with metastatic castration-resistant prostate cancer: The viable phase 3 randomized clinical trial","volume":"8","author":"Vogelzang","year":"2022","journal-title":"JAMA Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24267","article-title":"Long-term first-in-man phase I\/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy","volume":"82","author":"Tryggestad","year":"2022","journal-title":"Prostate"},{"key":"B48","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3390\/vaccines8040706","article-title":"DC-based vaccines for cancer immunotherapy","volume":"8","author":"Fu","year":"2020","journal-title":"Vaccines"},{"key":"B49","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12935-023-03108-0","article-title":"Development of dendritic cell loaded MAGE-A2 long peptide; a potential target for tumor-specific T cell-mediated prostate cancer immunotherapy","volume":"23","author":"Bakhshi","year":"2023","journal-title":"Cancer Cell Int"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20025","article-title":"NY-ESO-1 protein expression and humoral immune responses in prostate cancer","volume":"59","author":"Foss\u00e5","year":"2004","journal-title":"Prostate"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2020.08.004","article-title":"Generated SecPen_NY-ESO-1_ubiquitin-pulsed dendritic cell cancer vaccine elicits stronger and specific T cell immune responses","volume":"11","author":"Yang","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2011.11.083","article-title":"Antigen specific T-cell responses against tumor antigens are controlled by regulatory T cells in patients with prostate cancer","volume":"187","author":"Hadaschik","year":"2012","journal-title":"J Urol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx238","article-title":"Mechanisms regulating T-cell infiltration and activity in solid tumors","volume":"28","author":"Lanitis","year":"2017","journal-title":"Ann Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.immuni.2018.06.006","article-title":"Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy","volume":"49","author":"Li","year":"2018","journal-title":"Immunity"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/iju.2013.20.issue-10","article-title":"Circulating immunosuppressive cells of prostate cancer patients before and after radical prostatectomy: profile comparison","volume":"20","author":"Brusa","year":"2013","journal-title":"Int J Urol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23738","article-title":"Tumor-infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer","volume":"79","author":"Krueger","year":"2019","journal-title":"Prostate"},{"key":"B57","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40164-023-00407-0","article-title":"ScRNA-seq revealed an immunosuppression state and tumor microenvironment heterogeneity related to lymph node metastasis in prostate cancer","volume":"12","author":"Xin","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000541881","article-title":"The immune microenvironment in prostate cancer: A comprehensive review","author":"Novysedlak","year":"2024","journal-title":"Oncology"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.ccell.2021.09.005","article-title":"Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment","volume":"39","author":"Kfoury","year":"2021","journal-title":"Cancer Cell"},{"key":"B60","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41392-023-01569-3","article-title":"Amino acid metabolism in health and disease","volume":"8","author":"Ling","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B61","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12943-024-02164-y","article-title":"Molecular mechanisms and therapeutic significance of Tryptophan Metabolism and signaling in cancer","volume":"23","author":"Yan","year":"2024","journal-title":"Mol Cancer"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.biochi.2021.01.005","article-title":"Role of tryptophan metabolism in cancers and therapeutic implications","volume":"182","author":"Liu","year":"2021","journal-title":"Biochimie"},{"key":"B63","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.3390\/nu13124503","article-title":"Arginine and arginases modulate metabolism, tumor microenvironment and prostate cancer progression","volume":"13","author":"Matos","year":"2021","journal-title":"Nutrients"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20042028","article-title":"Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers","volume":"201","author":"Bronte","year":"2005","journal-title":"J Exp Med"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2200204","DOI":"10.1002\/bies.202200204","article-title":"Tumor-infiltrating lymphocyte therapy: Clinical aspects and future developments in this breakthrough cancer treatment","volume":"45","author":"Lee","year":"2023","journal-title":"BioEssays"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e1672494","DOI":"10.1080\/2162402X.2019.1672494","article-title":"Tumor-infiltrating lymphocytes from human prostate tumors reveal anti-tumor reactivity and potential for adoptive cell therapy","volume":"8","author":"Yunger","year":"2019","journal-title":"Oncoimmunology"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-018-0235-9","article-title":"Programming CAR-T cells to kill cancer","volume":"2","author":"Labanieh","year":"2018","journal-title":"Nat Biomed Eng"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01621-1","article-title":"HLA-independent T cell receptors for targeting tumors with low antigen density","volume":"28","author":"Mansilla-Soto","year":"2022","journal-title":"Nat Med"},{"key":"B69","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.imlet.2019.05.003","article-title":"The UniCAR system: a modular CAR T cell approach to improve the safety of CAR T cells","volume":"211","author":"Bachmann","year":"2019","journal-title":"Immunol Lett"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-017-0081-z","article-title":"Engineering car-t cells","volume":"5","author":"Zhang","year":"2017","journal-title":"biomark Res"},{"key":"B71","doi-asserted-by":"publisher","first-page":"3476","DOI":"10.3390\/cancers15133476","article-title":"Fine-tuning through generations: advances in structure and production of CAR-T therapy","volume":"15","author":"Zheng","year":"2023","journal-title":"Cancers"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/mto.2016.14","article-title":"CAR models: next-generation CAR modifications for enhanced T-cell function","volume":"3","author":"Abate-Daga","year":"2016","journal-title":"Mol Therapy Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"B74","doi-asserted-by":"publisher","first-page":"eaay8248","DOI":"10.1126\/scisignal.aay8248","article-title":"4-1BB costimulation promotes CAR T cell survival through noncanonical NF-\u03baB signaling","volume":"13","author":"Philipson","year":"2020","journal-title":"Sci Signaling"},{"key":"B75","doi-asserted-by":"publisher","first-page":"2378543","DOI":"10.1080\/21645515.2024.2378543","article-title":"Approved CAR-T therapies have reproducible efficacy and safety in clinical practice","volume":"20","author":"Goyco Vera","year":"2024","journal-title":"Hum Vaccines Immunother"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.24926\/iip.v12i4.4345","article-title":"Efficacy and safety of innovative experimental chimeric antigen receptor (CAR) T-cells versus axicabtagene ciloleucel (Yescarta) for the treatment of relapsed\/refractory large B-cell lymphoma (LBCL): matching adjusted indirect comparisons (MAICs) and systematic review","volume":"12","author":"Weinstein","year":"2021","journal-title":"Innov Pharm"},{"key":"B77","doi-asserted-by":"publisher","first-page":"2210046","DOI":"10.1080\/21645515.2023.2210046","article-title":"Kymriah\u00ae(tisagenlecleucel)\u2013an overview of the clinical development journey of the first approved CAR-T therapy","volume":"19","author":"Awasthi","year":"2023","journal-title":"Hum Vaccines Immunother"},{"key":"B78","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/01.COT.0000872268.55217.67","article-title":"Brexucabtagene Autoleucel (Tecartus\u2122)","volume":"44","author":"Lovell","year":"2022","journal-title":"Oncol Times"},{"key":"B79","doi-asserted-by":"publisher","first-page":"34","DOI":"10.5603\/ahp.97189","article-title":"Modern immunotherapy using CAR-T cells in haemato-oncology and solid tumors","volume":"55","author":"Bogacz","year":"2024","journal-title":"Acta Haematol Polonica"},{"key":"B80","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/01.COT.0000753336.18581.7d","article-title":"Idecabtagene Vicleucel (Abecma\u00ae)","volume":"43","author":"Robinson","year":"2021","journal-title":"Oncol Times"},{"key":"B81","doi-asserted-by":"publisher","first-page":"7085","DOI":"10.1182\/blood-2024-201606","article-title":"Efficacy of Carvykti in cartitude-4 versus alternative treatments from daratumumab clinical trials for the treatment of patients with lenalidomide-refractory multiple myeloma","volume":"144","author":"Delforge","year":"2024","journal-title":"Blood"},{"key":"B82","volume-title":"FDA Approves Obe-Cel for Adults With R\/R B-Cell Precursor Acute Lymphoblastic Leukemia","author":"Hoffman","year":"2004"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41585-024-00900-z","article-title":"Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer","author":"Bakht","year":"2024","journal-title":"Nat Rev Urol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"939","DOI":"10.3390\/cancers16050939","article-title":"The current landscape of prostate-specific membrane antigen (psma) imaging biomarkers for aggressive prostate cancer","volume":"16","author":"Al Saffar","year":"2024","journal-title":"Cancers"},{"key":"B85","doi-asserted-by":"publisher","first-page":"e11902","DOI":"10.15252\/emmm.201911902","article-title":"An IgG-based bispecific antibody for improved dual targeting in PSMA-positive cancer","volume":"13","author":"Zekri","year":"2021","journal-title":"EMBO Mol Med"},{"key":"B86","doi-asserted-by":"publisher","first-page":"106571","DOI":"10.1016\/j.jsbmb.2024.106571","article-title":"Left out in the cold: moving beyond hormonal therapy for the treatment of immunologically cold prostate cancer with CAR T cell immunotherapies","volume":"243","author":"Porter","year":"2024","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/S1525-0016(16)33446-3","article-title":"638. TGFBeta signaling blockade within PSMA targeted CAR human T cells for the eradication of metastatic prostate Cancer","volume":"24","author":"Kloss","year":"2016","journal-title":"Mol Ther"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol Ther"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04248-y","article-title":"Docetaxel enhances the therapeutic efficacy of PSMA-specific CAR-T cells against prostate cancer models by suppressing MDSCs","volume":"148","author":"Zhang","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2020.06.014","article-title":"PSMA-directed CAR T cells combined with low-dose docetaxel treatment induce tumor regression in a prostate cancer xenograft model","volume":"18","author":"Alzubi","year":"2020","journal-title":"Mol Therapy Oncol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-019-02206-w","article-title":"IL-23 and PSMA-targeted duo-CAR T cells in Prostate Cancer Eradication in a preclinical model","volume":"18","author":"Wang","year":"2020","journal-title":"J Trans Med"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7819-2-13","article-title":"Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer","volume":"2","author":"Zhigang","year":"2004","journal-title":"World J Surg Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203426","article-title":"Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer","volume":"19","author":"Gu","year":"2000","journal-title":"Oncogene"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41591-024-02979-8","article-title":"PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial","author":"Dorff","year":"2024","journal-title":"Nat Med"},{"key":"B96","doi-asserted-by":"publisher","first-page":"eadf0108","DOI":"10.1126\/sciadv.adf0108","article-title":"\u03b3\u03b4-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer","volume":"9","author":"Frieling","year":"2023","journal-title":"Sci Adv"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603494","article-title":"EpCAM (CD326) finding its role in cancer","volume":"96","author":"Baeuerle","year":"2007","journal-title":"Br J Cancer"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.10.026","article-title":"EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma","volume":"52","author":"Terris","year":"2010","journal-title":"J Hepatol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12865-014-0064-x","article-title":"Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM","volume":"16","author":"Deng","year":"2015","journal-title":"BMC Immunol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1806009","DOI":"10.1080\/2162402X.2020.1806009","article-title":"Potential lung attack and lethality generated by EpCAM-specific CAR-T cells in immunocompetent mouse models","volume":"9","author":"Qin","year":"2020","journal-title":"Oncoimmunology"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.3390\/cancers12071969","article-title":"Co-expression of IL-7 improves NKG2D-based CAR T cell therapy on prostate cancer by enhancing the expansion and inhibiting the apoptosis and exhaustion","volume":"12","author":"He","year":"2020","journal-title":"Cancers"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0232","article-title":"4-1BB antibody enhances cytotoxic activity of natural killer cells against prostate cancer cells via NKG2D agonist combined with IL-27","volume":"14","author":"Li","year":"2022","journal-title":"Immunotherapy"},{"key":"B103","doi-asserted-by":"publisher","first-page":"e901","DOI":"10.1002\/ctm2.v12.6","article-title":"Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumour efficacy against castration-resistant prostate cancer","volume":"12","author":"Wang","year":"2022","journal-title":"Clin Trans Med"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-014-9679-9","article-title":"A role for STEAP2 in prostate cancer progression","volume":"31","author":"Whiteland","year":"2014","journal-title":"Clin Exp Metastasis"},{"key":"B105","doi-asserted-by":"crossref","first-page":"e169655","DOI":"10.1172\/JCI169655","article-title":"Antitumor activity of AZD0754, a dnTGF \u03b2 RII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer","volume":"133","author":"Zanvit","year":"2023","journal-title":"J Clin Invest"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.09.004","article-title":"B7-H3 as a therapeutic target in advanced prostate cancer","volume":"83","author":"Guo","year":"2023","journal-title":"Eur Urol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0446","article-title":"Targeting radiation-resistant prostate cancer stem cells by B7-H3 CAR T cells","volume":"20","author":"Zhang","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B108","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jconrel.2020.08.021","article-title":"Antibody and antibody fragments for cancer immunotherapy","volume":"328","author":"Chen","year":"2020","journal-title":"J Controlled Release"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.02.034","article-title":"Antibody-based immunotherapy of cancer","volume":"148","author":"Weiner","year":"2012","journal-title":"Cell"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000091655.77601.0c","article-title":"Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen","volume":"170","author":"Bander","year":"2003","journal-title":"J Urol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2021.02.006","article-title":"Emerging prostate-specific membrane antigen-based therapeutics: small molecules, antibodies, and beyond","volume":"7","author":"Nauseef","year":"2021","journal-title":"Eur Urol Focus"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32072","article-title":"Phase 1\/2 study of fractionated dose lutetium-177\u2013labeled anti\u2013prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer","volume":"125","author":"Tagawa","year":"2019","journal-title":"Cancer"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS288","article-title":"A phase I\/II dose-escalation study of fractionated 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC) in patients with prior treatment with 177Lu-PSMA","volume":"41","author":"Nauseef","year":"2023","journal-title":"Am Soc Clin Oncol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2016.07.005","article-title":"Phase 1\/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer","volume":"34","author":"Milowsky","year":"2016","journal-title":"Urol Oncol: Semin Orig Invest"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.6_suppl.119","article-title":"Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane","volume":"31","author":"Petrylak","year":"2013","journal-title":"Am Soc Clin Oncol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0256","article-title":"Pasotuxizumab, a BiTE\u00ae immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings","volume":"13","author":"Hummel","year":"2021","journal-title":"Immunotherapy"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2023.02.010","article-title":"Phase 1 study of safety and preliminary clinical activity of JNJ-63898081, a PSMA and CD3 bispecific antibody, for metastatic castration-resistant prostate cancer","volume":"21","author":"Lim","year":"2023","journal-title":"Clin Genitourinary Cancer"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01994-1","article-title":"Identification of a high-risk immunogenic prostate cancer patient subset as candidates for T-cell engager immunotherapy and the introduction of a novel albumin-fused anti-CD3\u00d7 anti-PSMA bispecific design","volume":"127","author":"Glud","year":"2022","journal-title":"Br J Cancer"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002488","article-title":"Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release","volume":"9","author":"Dang","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1263","article-title":"A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer","volume":"13","author":"Gravdal","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2236","article-title":"Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance","volume":"16","author":"Tanaka","year":"2010","journal-title":"Nat Med"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0285","article-title":"A novel enolase-1 antibody targets multiple interacting players in the tumor microenvironment of advanced prostate cancer","volume":"21","author":"Chen","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00841-0","article-title":"Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases","volume":"18","author":"Tison","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2020.10.030","article-title":"Hot or not: tumor mutational burden (TMB) as a biomarker of immunotherapy response in genitourinary cancers","volume":"147","author":"Halbert","year":"2021","journal-title":"Urology"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2008.01.006","article-title":"Hypoxia in prostate cancer: a powerful shield against tumour destruction","volume":"34","author":"Marignol","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1471","article-title":"Radiotherapy decreases vascular density and causes hypoxia with macrophage aggregation in TRAMP-C1 prostate tumors","volume":"15","author":"Chen","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1172\/JCI96268","article-title":"Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy","volume":"128","author":"Jayaprakash","year":"2018","journal-title":"J Clin Invest"},{"key":"B128","doi-asserted-by":"publisher","first-page":"120057","DOI":"10.1016\/j.lfs.2021.120057","article-title":"The impact of hypoxia on immune state in cancer","volume":"286","author":"Mortezaee","year":"2021","journal-title":"Life Sci"},{"key":"B129","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13039-024-00680-6","article-title":"Loss of heterozygosity impacts MHC expression on the immune microenvironment in CDK12-mutated prostate cancer","volume":"17","author":"Lautert-Dutra","year":"2024","journal-title":"Mol Cytogenetics"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29070400","article-title":"Emerging biomarker-guided therapies in prostate cancer","volume":"29","author":"Deluce","year":"2022","journal-title":"Curr Oncol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2024.05.011","article-title":"Established and emerging liquid biomarkers for prostate cancer detection: A review","volume":"43","author":"Olson","year":"2024","journal-title":"Urol Oncol: Semin Orig Invest"},{"key":"B132","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s40168-022-01289-w","article-title":"Gut dysbiosis promotes prostate cancer progression and docetaxel resistance via activating NF-\u03baB-IL6-STAT3 axis","volume":"10","author":"Zhong","year":"2022","journal-title":"Microbiome"},{"key":"B133","doi-asserted-by":"publisher","first-page":"106883","DOI":"10.1016\/j.imlet.2024.106883","article-title":"Gut dysbiosis impacts the immune system and promotes prostate cancer","volume":"268","author":"Shyanti","year":"2024","journal-title":"Immunol Lett"},{"key":"B134","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/d41573-019-00182-w","article-title":"Trends in clinical development for PD-1\/PD-L1 inhibitors","volume":"19","author":"Durvalumab","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.117","article-title":"Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer","volume":"108","author":"Quezada","year":"2013","journal-title":"Br J Cancer"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2042","article-title":"The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer","volume":"22","author":"Gevensleben","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B137","doi-asserted-by":"publisher","first-page":"e1221555","DOI":"10.1080\/2162402X.2016.1221555","article-title":"Promoter methylation of the immune checkpoint receptor PD-1 (PDCD1) is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy","volume":"5","author":"Goltz","year":"2016","journal-title":"Oncoimmunology"},{"key":"B138","doi-asserted-by":"publisher","first-page":"79943","DOI":"10.18632\/oncotarget.13161","article-title":"PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy","volume":"7","author":"Gevensleben","year":"2016","journal-title":"Oncotarget"},{"key":"B139","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.3390\/cells10113166","article-title":"What do we have to know about PD-L1 expression in prostate cancer? A systematic literature review. Part 1: Focus on immunohistochemical results with discussion of pre-analytical and interpretation variables","volume":"10","author":"Palicelli","year":"2021","journal-title":"Cells"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24079","article-title":"Association between CD8 and PD-L1 expression and outcomes after radical prostatectomy for localized prostate cancer","volume":"81","author":"Vicier","year":"2021","journal-title":"Prostate"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.15562\/bmj.v12i2.4506","article-title":"PD-L1 overexpression in prostate cancer: a potential targeted therapy","volume":"12","author":"Aditya","year":"2023","journal-title":"Bali Med J"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2015.05.007","article-title":"PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma","volume":"89","author":"Cooper","year":"2015","journal-title":"Lung Cancer"},{"key":"B143","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12957-021-02325-z","article-title":"The immune checkpoint regulator PD-L1 expression are associated with clinical progression in prostate cancer","volume":"19","author":"He","year":"2021","journal-title":"World J Surg Oncol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.v144.12","article-title":"Expression of PD-L1 in tumor-associated nerves correlates with reduced CD8+ tumor-associated lymphocytes and poor prognosis in prostate cancer","volume":"144","author":"Mo","year":"2019","journal-title":"Int J Cancer"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.v12.15","article-title":"Prostate cancer cells synergistically defend against CD8+ T cells by secreting exosomal PD-L1","volume":"12","author":"Li","year":"2023","journal-title":"Cancer Med"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1111\/apm.2019.127.issue-8","article-title":"PD-L1 expression and deficient mismatch repair in ductal adenocarcinoma of the prostate","volume":"127","author":"Lindh","year":"2019","journal-title":"Apmis"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01494","article-title":"The clinicopathologic and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with prostate cancer: a systematic review and meta-analysis","volume":"9","author":"Li","year":"2019","journal-title":"Front Pharmacol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.5069","article-title":"Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 study","volume":"35","author":"Ott","year":"2017","journal-title":"J Clin Oncol"},{"key":"B149","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/JCO.19.01638","article-title":"Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J Clin Oncol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1002697","article-title":"Indirect stimulation of human V\u03b32V\u03b42 T cells through alterations in isoprenoid metabolism","volume":"187","author":"Wang","year":"2011","journal-title":"J Immunol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1025","article-title":"Alkylamines cause V\u03b39V\u03b42 T-cell activation and proliferation by inhibiting the mevalonate pathway","volume":"107","author":"Thompson","year":"2006","journal-title":"Blood"},{"key":"B152","doi-asserted-by":"publisher","first-page":"1989789","DOI":"10.1080\/2162402X.2021.1989789","article-title":"PD-1 checkpoint blockade enhances adoptive immunotherapy by human V\u03b32V\u03b42 T cells against human prostate cancer","volume":"10","author":"Nada","year":"2021","journal-title":"Oncoimmunology"},{"key":"B153","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S0952-7915(97)80087-8","article-title":"Co-stimulation in T cell responses","volume":"9","author":"Chambers","year":"1997","journal-title":"Curr Opin Immunol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1038\/35105024","article-title":"T-cell regulation by CD28 and CTLA-4","volume":"1","author":"Alegre","year":"2001","journal-title":"Nat Rev Immunol"},{"key":"B155","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1600-065X.2009.00770.x","article-title":"CD28 and CTLA-4 coreceptor expression and signal transduction","volume":"229","author":"Rudd","year":"2009","journal-title":"Immunol Rev"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.26.15074","article-title":"Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy","volume":"96","author":"Kwon","year":"1999","journal-title":"Proc Natl Acad Sci"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2010.09.007","article-title":"The emerging toxicity profiles of anti\u2013CTLA-4 antibodies across clinical indications","volume":"37","author":"Di Giacomo","year":"2010","journal-title":"Semin Oncol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2318","article-title":"A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer","volume":"13","author":"Small","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0813175106","article-title":"Anti-CTLA-4 therapy results in higher CD4+ ICOShi T cell frequency and IFN-\u03b3 levels in both nonmalignant and Malignant prostate tissues","volume":"106","author":"Chen","year":"2009","journal-title":"Proc Natl Acad Sci"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0762","article-title":"Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in human cancers","volume":"25","author":"Sharma","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.11.7169","article-title":"T Cell Ig-and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis","volume":"172","author":"Khademi","year":"2004","journal-title":"J Immunol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200939274","article-title":"TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines","volume":"39","author":"Hastings","year":"2009","journal-title":"Eur J Immunol"},{"key":"B163","doi-asserted-by":"publisher","first-page":"e30676","DOI":"10.1371\/journal.pone.0030676","article-title":"TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression","volume":"7","author":"Gao","year":"2012","journal-title":"PloS One"},{"key":"B164","doi-asserted-by":"publisher","first-page":"1010428317716628","DOI":"10.1177\/1010428317716628","article-title":"Analysis of Tim-3 as a therapeutic target in prostate cancer","volume":"39","author":"Piao","year":"2017","journal-title":"Tumor Biol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1752-y","article-title":"Dysfunction of PSA-specific CD8+ T cells in prostate cancer patients correlates with CD38 and Tim-3 expression","volume":"64","author":"Japp","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4405","article-title":"Blocking TIM-3 in treatment-refractory advanced solid tumors: a phase Ia\/b study of LY3321367 with or without an anti-PD-L1 antibody","volume":"27","author":"Harding","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2004.08.010","article-title":"Role of LAG-3 in regulatory T cells","volume":"21","author":"Huang","year":"2004","journal-title":"Immunity"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001014","article-title":"LAG-3: from molecular functions to clinical applications","volume":"8","author":"Maruhashi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01569-z","article-title":"LAG-3 as the third checkpoint inhibitor","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Nat Immunol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903879","article-title":"LAG-3 expression defines a subset of CD4+ CD25highFoxp3+ regulatory T cells that are expanded at tumor sites","volume":"184","author":"Camisaschi","year":"2010","journal-title":"J Immunol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.785091","article-title":"Immune checkpoint LAG3 and its ligand FGL1 in cancer","volume":"12","author":"Shi","year":"2022","journal-title":"Front Immunol"},{"key":"B172","doi-asserted-by":"publisher","first-page":"104773","DOI":"10.1016\/j.cellimm.2023.104773","article-title":"ATM-AMPK\u03b1 mediated LAG-3 expression suppresses T cell function in prostate cancer","volume":"393","author":"Zhang","year":"2023","journal-title":"Cell Immunol"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003776","article-title":"Phase I\/II study of the LAG-3 inhibitor ieramilimab (LAG525) \u00b1 anti-PD-1 spartalizumab (PDR001) in patients with advanced Malignancies","volume":"10","author":"Tan","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13407","article-title":"TIGIT as an emerging immune checkpoint","volume":"200","author":"Harjunp\u00e4\u00e4","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1111\/imr.2017.276.issue-1","article-title":"TIGIT and CD 96: new checkpoint receptor targets for cancer immunotherapy","volume":"276","author":"Dougall","year":"2017","journal-title":"Immunol Rev"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxab085","article-title":"DNAM-1 versus TIGIT: competitive roles in tumor immunity and inflammatory responses","volume":"33","author":"Shibuya","year":"2021","journal-title":"Int Immunol"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2016.10.002","article-title":"TIGIT: a key inhibitor of the cancer immunity cycle","volume":"38","author":"Manieri","year":"2017","journal-title":"Trends Immunol"},{"key":"B178","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1038\/s41467-018-05167-8","article-title":"TIGIT+ iTregs elicited by human regulatory macrophages control T cell immunity","volume":"9","author":"Riquelme","year":"2018","journal-title":"Nat Commun"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0464","article-title":"Restoration of T-cell effector function, depletion of Tregs, and direct killing of tumor cells: the multiple mechanisms of action of a-TIGIT antagonist antibodies","volume":"20","author":"Preillon","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B180","doi-asserted-by":"publisher","first-page":"101184","DOI":"10.1016\/j.esmoop.2023.101184","article-title":"Anti-TIGIT therapies for solid tumors: a systematic review","volume":"8","author":"Rousseau","year":"2023","journal-title":"ESMO Open"},{"key":"B181","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/pros.23756","article-title":"Identification of targets for prostate cancer immunotherapy","volume":"79","author":"Papanicolau\u2010Sengos","year":"2019","journal-title":"Prostate"},{"key":"B182","doi-asserted-by":"publisher","first-page":"216300","DOI":"10.1016\/j.canlet.2023.216300","article-title":"TIGIT immune checkpoint blockade enhances immunity of human peripheral blood NK cells against castration-resistant prostate cancer","volume":"568","author":"Wang","year":"2023","journal-title":"Cancer Lett"},{"key":"B183","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","article-title":"Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy","volume":"16","author":"Cai","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B184","doi-asserted-by":"publisher","first-page":"10661","DOI":"10.1038\/s41598-024-61477-6","article-title":"A novel anti-LAG-3\/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody","volume":"14","author":"Dai","year":"2024","journal-title":"Sci Rep"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2009.00768.x","article-title":"Fine tuning the immune response through B7-H3 and B7-H4","volume":"229","author":"Yi","year":"2009","journal-title":"Immunol Rev"},{"key":"B188","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1158\/1538-7445.AM2023-LB245","article-title":"Predictive value of co-expression patterns of immune checkpoint molecules for clinical outcomes of hematological Malignancies","volume":"35","author":"Chen","year":"2023","journal-title":"Chin J Cancer Res"},{"key":"B189","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/s12957-022-02810-z","article-title":"High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer","volume":"20","author":"Mollavelioglu","year":"2022","journal-title":"World J Surg Oncol"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1264327","article-title":"Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors","volume":"14","author":"Roy","year":"2023","journal-title":"Front Immunol"},{"key":"B191","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2020.08.007","article-title":"Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial","volume":"38","author":"Sharma","year":"2020","journal-title":"Cancer Cell"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1016\/S0093-7754(01)90148-4","article-title":"Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer","volume":"28","author":"Pienta","year":"2001","journal-title":"Semin Oncol"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS250","article-title":"Phase 1b\/2 study of pembrolizumab plus belzutifan and belzutifan alone in patients with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort J","volume":"42","author":"Yu","year":"2024","journal-title":"Am Soc Clin Oncol"},{"key":"B194","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.eururo.2022.02.023","article-title":"Pembrolizumab plus docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b\/2 KEYNOTE-365 cohort B study","volume":"82","author":"Evan","year":"2022","journal-title":"Eur Urol"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS5097","article-title":"A phase 2, multicenter, parallel-group, open-label study of vudalimab (XmAb20717), a PD-1 x CTLA-4 bispecific antibody, alone or in combination with chemotherapy or targeted therapy in patients with molecularly defined subtypes of metastatic castration-resistant prostate cancer","volume":"40","author":"Stein","year":"2022","journal-title":"Am Soc Clin Oncol"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002919","article-title":"Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment","volume":"9","author":"Subudhi","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2013.185","article-title":"Evolution of advanced technologies in prostate cancer radiotherapy","volume":"10","author":"Zaorsky","year":"2013","journal-title":"Nat Rev Urol"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00075-5","article-title":"Radiotherapy, immunity, and immune checkpoint inhibitors","volume":"25","author":"Lynch","year":"2024","journal-title":"Lancet Oncol"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.5565","article-title":"Safety and clinical activity of atezolizumab (atezo)+ radium-223 dichloride (r-223) in 2L metastatic castration-resistant prostate cancer (mCRPC): Results from a phase Ib clinical trial","author":"Morris","year":"2020","journal-title":"Am Soc Clin Oncol"},{"key":"B200","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.canlet.2013.09.018","article-title":"Abscopal effects of radiation therapy: a clinical review for the radiobiologist","volume":"356","author":"Siva","year":"2015","journal-title":"Cancer Lett"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti\u2013CTLA-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005060","article-title":"Antitumor efficacy of 90Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors","volume":"10","author":"Potluri","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B204","doi-asserted-by":"publisher","first-page":"e229","DOI":"10.1016\/j.ijrobp.2023.06.1141","article-title":"Dual immune checkpoint therapy combined with radiotherapy treats castration-resistant prostate cancer","volume":"117","author":"Eximond","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-2499","article-title":"Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells","volume":"72","author":"Tang","year":"2012","journal-title":"Cancer Res"},{"key":"B206","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1016\/j.ccell.2023.10.006","article-title":"Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer","volume":"41","author":"Hawley","year":"2023","journal-title":"Cancer Cell"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3782","article-title":"Direct therapeutic applications of calcium electroporation to effectively induce tumor necrosis","volume":"72","author":"Frandsen","year":"2012","journal-title":"Cancer Res"},{"key":"B208","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1038\/s41467-021-24132-6","article-title":"Irreversible electroporation augments checkpoint immunotherapy in prostate cancer and promotes tumor antigen-specific tissue-resident memory CD8+ T cells","volume":"12","author":"Burbach","year":"2021","journal-title":"Nat Commun"},{"key":"B209","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.3390\/cancers11091280","article-title":"STAT3, a master regulator of anti-tumor immune response","volume":"11","author":"R\u00e9b\u00e9","year":"2019","journal-title":"Cancers"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B211","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00262-021-02915-6","article-title":"Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer","volume":"70","author":"Witt","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B212","doi-asserted-by":"publisher","first-page":"153939","DOI":"10.1016\/j.phymed.2022.153939","article-title":"Traditional Chinese medicine CFF-1 exerts a potent anti-tumor immunity to hinder tumor growth and metastasis in prostate cancer through EGFR\/JAK1\/STAT3 pathway to inhibit PD-1\/PD-L1 checkpoint signaling","volume":"99","author":"Zhang","year":"2022","journal-title":"Phytomedicine"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004198","article-title":"Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)","volume":"10","author":"McNeel","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-019-0176-8","article-title":"A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer","volume":"23","author":"Ross","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B215","doi-asserted-by":"publisher","first-page":"312","DOI":"10.21037\/tlcr-23-83","article-title":"Differential organ-specific tumor response to first-line immune checkpoint inhibitor therapy in non-small cell lung cancer\u2014a retrospective cohort study","volume":"12","author":"Wang","year":"2023","journal-title":"Trans Lung Cancer Res"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B217","doi-asserted-by":"publisher","first-page":"bvab100","DOI":"10.1210\/jendso\/bvab100","article-title":"Endocrine toxicity and outcomes in patients with metastatic Malignancies treated with immune checkpoint inhibitors","volume":"5","author":"Al Ashi","year":"2021","journal-title":"J Endocr Soc"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0075","article-title":"Immune checkpoint inhibitor-induced thyroiditis is associated with increased intrathyroidal T lymphocyte subpopulations","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29100629","article-title":"Long-term toxicities of immune checkpoint inhibitor (ICI) in melanoma patients","volume":"29","author":"Tong","year":"2022","journal-title":"Curr Oncol"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1111\/imr.v318.1","article-title":"Effects of Immune-related adverse events (irAEs) and their treatment on antitumor immune responses","volume":"318","author":"Blum","year":"2023","journal-title":"Immunol Rev"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol"},{"key":"B223","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/ITT.S141577","article-title":"Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events","volume":"6","author":"Davies","year":"2017","journal-title":"ImmunoTargets Ther"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.36401\/JIPO-23-9","article-title":"Evaluating immune-related adverse events using PRO-CTCAE in a phase II study of ipilimumab for hormone-sensitive prostate cancer","volume":"6","author":"de Almeida","year":"2023","journal-title":"J Immunother Precis Oncol"},{"key":"B225","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13073-024-01285-9","article-title":"Gut microbiome for predicting immune checkpoint blockade-associated adverse events","volume":"16","author":"Hu","year":"2024","journal-title":"Genome Med"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14626","article-title":"Gut microbiota shed new light on the management of immune-related adverse events","volume":"13","author":"Tan","year":"2022","journal-title":"Thorac Cancer"},{"key":"B227","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.3390\/cancers15051629","article-title":"Predictive biomarkers for checkpoint inhibitor immune-related adverse events","volume":"15","author":"Les","year":"2023","journal-title":"Cancers"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1164724","article-title":"Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor","volume":"14","author":"Hamada","year":"2023","journal-title":"Front Immunol"},{"key":"B229","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3390\/cancers11040539","article-title":"Strategies to improve cancer immune checkpoint inhibitors efficacy, other than abscopal effect: A systematic review","volume":"11","author":"Longo","year":"2019","journal-title":"Cancers"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1192762","article-title":"Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: a systematic review and meta-analysis","volume":"10","author":"Fitzsimmons","year":"2023","journal-title":"Front Med"},{"key":"B231","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00262-024-03663-z","article-title":"Efficacy of immune checkpoint inhibitors differs in various status of carcinoma: a study based on 29 cohorts with 3255 participants","volume":"73","author":"Wu","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B232","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41591-024-03398-5","article-title":"Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data","author":"Yoo","year":"2025","journal-title":"Nat Med"},{"key":"B233","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4251\/wjgo.v14.i1.19","article-title":"Biomarkers for response to immune checkpoint inhibitors in gastrointestinal cancers","volume":"14","author":"Li","year":"2022","journal-title":"World J Gastrointest Oncol"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.4008","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study","volume":"26","author":"Berthold","year":"2008","journal-title":"J Clin Oncol"},{"key":"B235","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA: Cancer J Clin"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.09.008","article-title":"Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial","volume":"75","author":"Boev\u00e9","year":"2019","journal-title":"Eur Urol"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"New Engl J Med"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00339","article-title":"Olaparib for the treatment of patients with metastatic castration-resistant prostate cancer and alterations in BRCA1 and\/or BRCA2 in the PROfound Trial","volume":"42","author":"Mateo","year":"2024","journal-title":"J Clin Oncol"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol"},{"key":"B241","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1200\/JCO.20.01576","article-title":"Pan-AKT inhibitor capivasertib with docetaxel and prednisolone in metastatic castration-resistant prostate cancer: a randomized, placebo-controlled phase II trial (ProCAID)","volume":"39","author":"Crabb","year":"2021","journal-title":"J Clin Oncol"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00580-8","article-title":"Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial","volume":"398","author":"Sweeney","year":"2021","journal-title":"Lancet"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1583363\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T06:12:07Z","timestamp":1750227127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1583363\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":242,"alternative-id":["10.3389\/fimmu.2025.1583363"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1583363","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"article-number":"1583363"}}